Efficacy and predictors of response of lenalidomide and rituximab in patients with treatment-naive and relapsed CLL

This phase 2 study was conducted to prospectively evaluate how clinical and biological factors correlate with outcome in patients with treatment-naive (TN) and relapsed (R) chronic lymphocytic leukemia (CLL) treated with lenalidomide and rituximab. Oral lenalidomide 10 mg was administered daily star...

תיאור מלא

שמור ב:
מידע ביבליוגרפי
הוצא לאור ב:Blood Adv
Main Authors: Strati, Paolo, Takahashi, Koichi, Peterson, Christine B., Keating, Michael J., Thompson, Philip A., Daver, Naval G., Jain, Nitin, Burger, Jan A., Estrov, Zeev, O'Brien, Susan M., Kantarjian, Hagop M., Wierda, William G., Futreal, P. Andrew, Ferrajoli, Alessandra
פורמט: Artigo
שפה:Inglês
יצא לאור: American Society of Hematology 2019
נושאים:
Lymphoid Neoplasia
גישה מקוונת:https://ncbi.nlm.nih.gov/pmc/articles/PMC6517659/
https://ncbi.nlm.nih.gov/pubmed/31076409
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1182/bloodadvances.2019031336
תגים: הוספת תג
אין תגיות, היה/י הראשונ/ה לתייג את הרשומה!

פריטים דומים